Immunological landscape of consensus clusters in colorectal cancer
Metrics: PDF 1014 views | HTML 1801 views | ?
Pawel Karpinski1, Joanna Rossowska2 and Maria Malgorzata Sasiadek1
1Department of Genetics, Wroclaw Medical University, Wroclaw, Poland
2L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
Pawel Karpinski, email: email@example.com
Keywords: colorectal; clusters; immunotherapy; immune modifiers
Received: June 21, 2017 Accepted: September 20, 2017 Published: October 27, 2017
Recent, large-scale expression–based subtyping has advanced our understanding of the genomic landscape of colorectal cancer (CRC) and resulted in a consensus molecular classification that enables the categorization of most CRC tumors into one of four consensus molecular subtypes (CMS). Currently, major progress in characterization of immune landscape of tumor-associated microenvironment has been made especially with respect to microsatellite status of CRCs. While these studies profoundly improved the understanding of molecular and immunological profile of CRCs heterogeneity less is known about repertoire of the tumor infiltrating immune cells of each CMS.
In order to comprehensively characterize the immune landscape of CRC we re-analyzed a total of 15 CRC genome-wide expression data sets encompassing 1597 tumors and 125 normal adjacent colon tissues. After quality filtering, CRC clusters were discovered using a combination of multiple clustering algorithms and multiple validity metrics. CIBERSORT algorithm was used to compute relative proportions of 22 human leukocyte subpopulations across CRC clusters and normal colon tissue. Subsequently, differential expression specific to tumor epithelial cells was calculated to characterize mechanisms of tumor escape from immune surveillance occurring in particular CRC clusters.
Our results not only characterize the common and cluster-specific influx of immune cells into CRCs but also identify several deregulated gene targets that may contribute to improvement of immunotherapeutic strategies in CRC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.